Document is current

Article History

Received: 5 June 2025

Accepted: 25 December 2025

First Online: 25 January 2026

Disclosures

: This article is a revised and expanded version of the following conference abstracts entitled “Delays in breast cancer surgery during the COVID-19 pandemic: A population-based analysis” presented as posters during the following meetings: San Antonio Breast Cancer Symposium, San Antonio, December 2023. Ko G, Roberts A, Li Q, Liu N, Zhong T, Amir E, Koch A, Covelli A, Freitas V, Reel E, Eskander A. Delays in breast cancer surgery during the COVID-19 pandemic: A population-based analysis. In: Proceedings of the American Association for Cancer Research (AACR) Annual Meeting, San Diego, CA, USA, April 2024. Cancer Res. 2024;84(9_Suppl):PO3-23-02. . Society of Surgical Oncology Annual Meeting, Atlanta, Georgia, USA, 2024. Society of Surgical Oncology SSO 2024 Annual Meeting. Ann Surg Oncol 2024;31(Suppl 1):1–294. . Dr. Eitan Amir reports receiving honoraria from Seagen, Gilead, Pfizer, and AstraZeneca. Additional honoraria were directed to his institution from Novartis. He has served in a consulting or advisory role for AstraZeneca and Novartis.

: The study was approved by the Research Ethics Board of University Health Network, Toronto, Canada (22-5809) on December 8, 2022.

: Due to the retrospective nature of the study, formal consent was not required, as per the guidelines of Research Ethics Board of University Health Network, Toronto, Canada and in accordance with ICES policies.